Immuno-Oncology | Specialty

Molecular Testing in Ovarian Cancer

November 20th 2017

Immunotherapy Continues to Shape Future Bladder Cancer Paradigm

November 20th 2017

Maria De Santis, MD, discusses the findings of KEYNOTE-045 and the future of immunotherapy in the treatment landscape of bladder cancer.

Next Steps in Bladder Cancer to Include Combination Immunotherapy

November 19th 2017

Andrea Necchi, MD, discusses the evolution of bladder cancer therapies, the challenge with the currently available agents, and the next steps and clinical trials being conducted in the field.

Immunotherapy Overtakes Targeted Therapy as First-Line Standard of Care for mRCC

November 18th 2017

An extension in overall survival seen with the combination of nivolumab and ipilimumab has completely changed the standard of care for patients with metastatic renal cell carcinoma.

Pembrolizumab, Atezolizumab New Standards for Bladder Cancer

November 18th 2017

A wealth of new clinical trial data for immune checkpoint inhibitors has recently been reported for the treatment of patients with metastatic muscle-invasive urothelial carcinoma.

Dr. Necchi on Impact of PD-1 Inhibition in Bladder Cancer

November 17th 2017

Andrea Necchi, MD, a medical oncologist at the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, discusses the impact of PD-1 inhibition in bladder cancer as well as the promise with combination strategies.

Dr. Paulson Discusses Acquired Resistance to Immunotherapy

November 17th 2017

Kelly Paulson, MD, fellow, Seattle Cancer Care Alliance, discusses acquired resistance to immunotherapy during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.

Dr. Dorff on Current Agents for Patients With mCRPC

November 16th 2017

Tanya B. Dorff, MD, associate professor of clinical medicine, University of Southern California, discusses current agents available for patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Grivas on Combining Chemotherapy and Immunotherapy in Bladder Cancer

November 14th 2017

Petros Grivas, MD, PhD, medical oncologist, Cleveland Clinic, discusses combining chemotherapy and immunotherapy as a treatment approach for patients with bladder cancer.

Soft Tissue Sarcoma: An Increasing Number of Options

November 14th 2017

Second-Line Therapy Options: Role of Trabectedin

November 14th 2017

Soft Tissue Sarcoma: Decisions Following Progression

November 14th 2017

Changing Treatment Landscape in Soft Tissue Sarcoma

November 14th 2017

Olaratumab's Role in Soft Tissue Sarcoma

November 14th 2017

Soft Tissue Sarcoma: Selecting Among Frontline Options

November 14th 2017

First-line Options in Soft Tissue Sarcoma

November 14th 2017

Initial Treatment Approach in Soft Tissue Sarcoma

November 14th 2017

Common Pitfalls With Treating Soft Tissue Sarcoma

November 14th 2017

Collaboration of Experts in Soft Tissue Sarcoma

November 14th 2017

Ongoing Management Decisions in Soft Tissue Sarcoma

November 14th 2017